Ganglioside complexes as new target antigens in Guillain-Barré syndrome.

Third Department of Internal Medicine, National Defense Medical College, Saitama, Japan.
Annals of Neurology (Impact Factor: 11.19). 11/2004; 56(4):567-71. DOI: 10.1002/ana.20222
Source: PubMed

ABSTRACT Antibodies specific for a complex of gangliosides GD1a and GD1b (GD1a/GD1b) were found in sera from eight of 100 patients with Guillain-Barre syndrome (GBS) by the use of enzyme-linked immunosorbent assay and thin-layer chromatogram immunostaining. Those sera also had antibody activities to such ganglioside complexes as GD1a/GM1, GD1b/GT1b, and GM1/GT1b but had little or no reactivity to the each isolated antigen. Clustered epitopes of the ganglioside complex in the plasma membrane may be targeted by such an antibody, and interaction between the antibody and ganglioside complex may induce the neuropathy.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Autoantibodies are involved in the pathogenesis of several neuroimmunological diseases. Anti-neurofascin antibodies are detected in sera from some patients with multiple sclerosis and have been shown to induce axonal damage and exacerbation of experimental autoimmune encephalomyelitis. Recently, Lindner et al reported a discrepancy between the activity of the anti-neurofascin antibodies in vivo and that in a cell-based assay. This may be due to the effects of antibody fine specificity and the local molecular environment of the target membrane on the reactivity of the autoantibodies, as reported in diseases such as Guillain-Barré syndrome. Thus, an assay system that better reflects the environment in vivo is needed to evaluate the pathogenetic roles of autoantibodies.
    Experimental Neurology 10/2013; · 4.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Humans with autoimmune peripheral neuropathies frequently harbour serum antibodies to single glycosphingolipids, especially gangliosides. Recently it has been appreciated that glycolipid and lipid complexes, formed from two or more individual species, can interact to create molecular shapes capable of being recognised by these autoantibodies whilst not binding to the single individuals. As a result of this, novel autoantibody targets have been identified. This newly termed 'combinatorial glycomic' approach has provided the impetus to redesigning the assay methodologies traditionally used in the neuropathy-associated autoantibody field. Combinatorial glycoarrays can be readily constructed in house using lipids of interest. Herein we especially highlight the role of the neutral lipids cholesterol and galactocerebroside in modifying glycosphingolipid orientation that subsequently favours or inhibits autoantibody binding.
    Current opinion in chemical biology 02/2014; 18C:78-86. · 8.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: IgM antibodies against gangliosides and their complexes were studied in sera from 54 patients with polyneuropathy and IgM monoclonal gammopathy (IgM-PNP) without anti-MAG antibodies. Anti-ganglioside antibodies were found in 19 (35%) patients. Five (9%) patients had antibodies against ganglioside complexes. IgM antibodies against gangliosides activated complement in vitro. Light chain usage was restricted to kappa or lambda in most, but not all patients. In conclusion, anti-ganglioside antibodies in IgM-PNP are common, display pathogenic properties and do not always arise from a monoclonal B cell proliferation.
    Journal of neuroimmunology 01/2014; · 2.84 Impact Factor